Department of Nephrology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.
Clin Immunol. 2024 May;262:110182. doi: 10.1016/j.clim.2024.110182. Epub 2024 Mar 6.
Therapeutic strategies for autoimmune diseases have been based on the use of glucocorticoids and immunosuppressive agents that broadly suppress immune responses. Therefore, organ damage from long-term use and infections due to immunocompromised status have been significant issues. Safer immunosuppressants and biological agents are now available, but there is still an urgent need to develop specific drugs to replace glucocorticoids. T-lymphocytes, central players in immune responses, could be crucial targets in the treatment of autoimmune diseases. Extensive research has been conducted on the phenotypic changes of T-cells in systemic lupus erythematosus, which has led to the discovery of various therapeutic strategies. In this comprehensive review, we discuss novel treatment approaches and target molecules with expected effectiveness in humans and mice, based on research for lymphocytes involved in autoimmune diseases, especially T-cells in SLE.
自身免疫性疾病的治疗策略一直基于使用糖皮质激素和免疫抑制剂，这些药物广泛抑制免疫反应。因此，长期使用导致的器官损伤和免疫抑制状态下的感染一直是重大问题。现在有更安全的免疫抑制剂和生物制剂，但仍迫切需要开发特异性药物来替代糖皮质激素。T 淋巴细胞作为免疫反应的核心参与者，可能是治疗自身免疫性疾病的关键靶点。人们对系统性红斑狼疮中 T 细胞的表型变化进行了广泛研究，这导致了各种治疗策略的发现。在这篇综述中，我们根据涉及自身免疫性疾病的淋巴细胞，特别是系统性红斑狼疮中的 T 细胞的研究，讨论了在人类和小鼠中具有预期疗效的新型治疗方法和靶分子。
